Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer

NCT03477396 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03477396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03477396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
June 14, 2018
Completion date
June 5, 2023
Enrollment
2 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor and/or progesterone receptor positive, her2/neu negative, stage iv breast cancer ajcc v6 and v7